slides · global inventory
Paragraph
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 118,471
Current window 17,821-17,850
Pages 3,950
Rows per page 30
Component
17,821-17,850 of 118,471
170
The slide uses a combination of narrative argument and a cited abstract to highlight a potential safety oversight.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 3 hits
171
The slide uses two distinct text columns to present evidence from 2008 and 2009 papers regarding the toxicity profile of H3R compounds.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 3 hits
181
The slide presents a clinical case narrative alongside screenshots of FDA FAERS database records.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 3 hits
186
The slide presents a clinical case study from the FDA FAERS database, highlighting a potential drug-drug interaction or confounding factor.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 3 hits
188
This is a raw FDA FAERS FOIA case report document.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 3 hits
190
This slide presents raw clinical case data from the FDA FAERS database to support a hypothesis about drug interactions.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 3 hits
225
The slide uses a strong, accusatory tone to undermine the validity of the clinical trial results.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 3 hits
229
The slide highlights a specific regulatory failure/contradiction regarding the acceptance of post-hoc analysis in clinical trials.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 3 hits
231
The slide uses a 'villain' framing for the FDA reviewer's oversight.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 3 hits
237
The slide uses a 'villain' framing to discredit the reliability of clinical data originating from Russia and Eastern Europe.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 3 hits
262
The slide uses a Q&A format to validate the negative thesis regarding Wakix market performance.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 3 hits
271
The slide uses highlighted text to emphasize negative feedback from a key opinion leader.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 3 hits
273
The slide uses a Q&A transcript format to validate the summary points provided at the top.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 3 hits
275
The slide uses direct quotes from a consultation call to challenge the drug's safety and efficacy profile.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 3 hits
280
The slide highlights potential regulatory/compliance risks (lack of monitoring) and commercial opacity (pricing) regarding the drug Wakix.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 3 hits
282
The slide uses bolding and highlighting to emphasize negative sentiment from a key opinion leader.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 3 hits
291
The slide uses a Q&A format to provide expert validation that scheduling is not a significant barrier to prescription.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 3 hits
297
The slide uses a 'preempt_rebuttal' or 'expose_contradiction' style to challenge the scientific validity of a drug's mechanism of action claims.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 3 hits
303
The slide uses a direct excerpt from a scientific paper to undermine a previous scientific claim.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 3 hits
305
The slide uses underlined text to emphasize key findings that contradict the company's narrative.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 3 hits
317
The slide uses highlighted text to emphasize key admissions of quid pro quo arrangements.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 3 hits
325
The slide uses a 'fraud-exposure' narrative by contrasting the official label with market reality.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 3 hits
327
The slide uses a Q&A transcript format to expose potentially fraudulent sales practices.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 3 hits
343
The slide uses a combination of narrative summary and Q&A transcript to build a case of corporate malfeasance.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 3 hits
22
The slide uses a Q&A format to expose potential accounting fraud and product failure.Lasertec Corporation (6920) · Scorpion Capital
Activist deck Short seller Beat · Allegations of accounting irregularities3 hits
26
The slide uses a Q&A format to present negative expert testimony regarding Lasertec's A150 and A300 products.Lasertec Corporation (6920) · Scorpion Capital
Activist deck Short seller Beat · Allegations of accounting irregularities3 hits
30
The slide presents a series of Q&A and narrative excerpts highlighting technical limitations of Lasertec's actinic inspection tools and the competitive threat from KLA.Lasertec Corporation (6920) · Scorpion Capital
Activist deck Short seller Beat · Allegations of accounting irregularities3 hits
40
The slide uses a quote from an industry consultant to challenge the 'monopoly' narrative surrounding Lasertec's market position.Lasertec Corporation (6920) · Scorpion Capital
Activist deck Short seller Beat · Technical issues with Lasertec's products3 hits
88
The slide contrasts KLA and Lam Research's audit reports with the explicit fraud case of MagnaChip.Lasertec Corporation (6920) · Scorpion Capital
Activist deck Short seller 3 hits
92
The slide contrasts the CEO's optimistic outlook in October 2023 with the reality of low margins in Q1, followed by a defensive explanation in January 2024.Lasertec Corporation (6920) · Scorpion Capital
Activist deck Short seller 3 hits